АНТИТЕЛА И АНТИ-АНТИТЕЛА К СТЕРОИДНЫМ ГОРМОНАМ И РИСК РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ

Antibodies against sex steroid hormones are known to modulate their serum concentration and  inhibit experimental breast cancer (BC). Hence, these effects could be changed by according anti-idiotypic  antibodies. However, relationships between antibodies and anti-idiotypic antibodies and BC in women are still  poorly studied. The aim of this study was to identify possible associations between occurrence of antibodies  against estradiol and progesterone (IgG-Es1and IgG-Pg1) and according antiidiotypic antibodies (IgG-Es2  and IgG-Pg2), and postmenopausal BC.  Eighty-nine  healthy  women  and  273  BC  patients  were  examined.  A  non-competitive  solid  phase  immunoassay for IgG-Es1 and IgG-Pg1 was performed using estradiol and progesterone conjugates with bovin  serum albumin as antigens. Monoclonal antibodies against Es and Pg as antigens have been used for noncompetitive solid phase immunoassay of IgG-Es2 and IgG-Pg2.  Results: absence of both IgG-Es1 and IgG-Pg1 was revealed in 53.9% of healthy donors and 41.0% of  BC patients (p = 0.04; OR = 0.6). Presence of IgG-Es1 without IgG-Pg1, or IgG-Pg1 without IgG-Es1was  detected for, respectively, 15.7% and 20.2% of healthy women, and in 10.3% and 7.7% of BC patients (p > 0.05).  Simultaneous increase of both IgG-Es1 and IgG-Pg1 was revealed in 10.1% of healthy donors and in 41.0%  of BC patients (p < 0.0001; OR = 5.3). Absence of a single antibogy (IgG-Es2 or IgG-Pg2) showed similar  frequency in the groups under study. Simultaneous increase of both IgG-Es2 and IgG-Pg2 was detected in  52.8% of healthy women and 34.8% of BC patients (p = 0.03; OR = 0.4). Conclusion: We have first revealed  an immunostimulating synergistic effect of antibodies against sex steroid hormones and immunoinhibitory  synergistic effect of appropriate anti-idiotypic antibodies upon the postmenopausal breast cancer risk.